Véronique Diéras, MD, on HER2-Negative, BRCA-Mutated Breast Cancer: Veliparib Plus Carboplatin/Paclitaxel
ESMO 2019 CongressVéronique Diéras, MD, of Institut Curie Paris & Saint Cloud, discusses results from the phase III BROCADE 3 trial, which investigated the PARP inhibitor veliparib in combination with carboplatin/paclitaxel in patients with advanced HER2-negative, germline BRCA–mutated breast cancer (Abstract LBA9).
Related Videos
Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as ...
Aleix Prat, MD, PhD, on a HER2-Positive Breast Cancer Biomarker: Results From the PAM50 Trial
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyon...
Suresh S. Ramalingam, MD, on Osimertinib vs Comparator EGFR TKI in EGFR-Mutated NSCLC: The FLAURA Trial
Suresh S. Ramalingam, MD, of Emory University, discusses results from the final overall survival analysis of the phase III FLAURA trial in EGFR-mutated advanced non–...
Isabelle Ray-Coquard, MD, PhD, on Ovarian Cancer: Olaparib Plus Bevacizumab
Isabelle Laure Ray-Coquard, MD, PhD, of the Centre Leon Bérard, discusses phase III study findings in patients with newly diagnosed, advanced ovarian cancer who received olap...
Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma
Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, discusses findings from a study that showed new staging criteria should be considered for patients diagnosed wi...
